1. Home
  2. MBAI vs RNAZ Comparison

MBAI vs RNAZ Comparison

Compare MBAI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.66

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$8.91

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
RNAZ
Founded
2004
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
8.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MBAI
RNAZ
Price
$1.66
$8.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$280.00
AVG Volume (30 Days)
7.2M
609.3K
Earning Date
03-30-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$6.08
52 Week High
$3.92
$399.00

Technical Indicators

Market Signals
Indicator
MBAI
RNAZ
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MBAI
RNAZ

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: